Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics (NYSE: DGX) will report first quarter 2026 financial results on April 21, 2026 before the market opens and will host a conference call at 8:30 a.m. ET.
The live webcast, earnings release, dial‑in numbers, passcode, and replay details will be posted at the company investor website. Telephone replay is available from about 10:30 a.m. ET on April 21 until midnight ET on May 5, 2026.
Investors are encouraged to review the company's SEC filings for risk factors and historical financial information.
Quest Diagnostics (NYSE: DGX) elected Timothy Wentworth to its board of directors on March 12, 2026, bringing the board to eleven members. Mr. Wentworth is a former CEO of Walgreens Boots Alliance, Evernorth, and Express Scripts with extensive pharmacy, health plan, and operations experience.
The company said his background in employer, plan, and consumer channels and HR and operations expertise will support Quest's diagnostic and health-services strategy.
Quest Diagnostics (NYSE: DGX) launched Quest AI Companion on March 2, 2026, an AI chat feature in MyQuest that analyzes up to five years of Quest lab data to explain results, highlight trends, and help users prepare questions for clinicians.
Powered by Google’s Gemini models via a strategic Google Cloud collaboration (established March 2025), the tool operates within the HIPAA-compliant MyQuest platform and is available to adult users; it is educational and not a substitute for professional medical advice.
Quest Diagnostics (NYSE: DGX) named Benjamin Beauvalot senior vice president, chief strategy and M&A officer, effective Feb. 26, 2026. He brings more than 20 years of strategy, M&A and transformation experience from Danaher, Patheon and Banner Life Sciences.
Mr. Beauvalot will lead growth strategy, mergers and acquisitions, strategic partnerships and integrations, reporting to Jim Davis and joining the executive leadership team. He succeeds Dermot Shorten, who will retire in Q2 2026 after overseeing nearly 80 business combinations, including about 20 hospital outreach lab acquisitions.
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026 at 8:00 a.m. ET.
The fireside chat and Q&A will be webcast live on the company's investor relations site, with an archived replay available within 24 hours and accessible through March 25, 2026.
Quest Diagnostics (NYSE: DGX) reported fourth-quarter 2025 net revenues of $2.81 billion (up 7.1%) and full-year 2025 net revenues of $11.04 billion (up 11.8%). Reported diluted EPS was $2.18 for Q4 and $8.75 for full year; adjusted diluted EPS was $2.42 for Q4 and $9.85 for the year.
The company generated $1.89 billion of cash from operations in 2025, raised its quarterly dividend 7.5% to $0.86 per share, and provided 2026 guidance of $11.70–$11.82 billion in revenues and adjusted diluted EPS of $10.50–$10.70.
Quest Diagnostics (NYSE: DGX) announced a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80, effective with the dividend payable on April 20, 2026 to shareholders of record on April 6, 2026.
The change raises the annual cash dividend to $3.44 per share and follows 15 consecutive years of dividend increases. The Board also authorized a $1 billion increase in the share repurchase program, added to approximately $0.4 billion available as of December 31, 2025.
Quest Diagnostics (NYSE: DGX) launched Quest Flow Cytometry MRD for Myeloma on Feb 2, 2026, an ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma.
The test reports sensitivity comparable to next-generation sequencing, five-day specimen stability versus three days for conventional flow, works without a pre-treatment baseline aspirate, and is promoted as lower cost to support broader access and clinical-trial monitoring.
Quest Diagnostics (NYSE: DGX) announced it was named to Fortune's 2026 World's Most Admired Companies list for the 12th consecutive year and ranked #2 in the "Health Care: Pharmacy and Other Services" industry category.
The recognition is based on nine corporate‑reputation attributes surveyed by Korn Ferry and Fortune, covering product quality, innovation, long‑term value, financial profile, responsibility, and people management. Quest highlighted its 55,000 colleagues and role delivering diagnostic insights from one of the largest de‑identified clinical lab databases, serving roughly one in three U.S. adults annually.
Sonora Quest Laboratories (NYSE:DGX) named Jennifer Erickson as Chief Executive Officer‑Elect, succeeding longtime CEO David Dexter, who will retire effective March 31, 2026. Dexter will work with Erickson starting Feb. 2, 2026 to complete a planned transition. Dexter led the company for more than 26 years, overseeing growth to a market‑share leadership position in Arizona and operations performing more than 100 million diagnostic tests per year. Erickson brings over 20 years of health‑care leadership and previously served as Sonora Quest CFO (1999–2004).